MedTrace Logo

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

NCT02089295 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-04-04

No results posted yet for this study

Summary

To evaluate the dose proportionality of 5 mg, 20 mg and 40 mg of PF 00345439 formulation under fed conditions in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Oxycodone

One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions

DRUG

Oxycodone

One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions

Sponsors & Collaborators

  • Pain Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02089295 on ClinicalTrials.gov